Discovery and Evaluation of Anticancer Drugs
Course Information
Date: AnytimeDuration: 30 Minutes
Location: Virtual
Audience: ACVIM, ECEIM, ECVIM-CA and ECVN Diplomates and candidates
Specialty: Oncology
Type: On Demand
CE Hours: 0.5
Course Overview
Pharmaceuticals are an important tool in the treatment of cancer. This course gives a high level view of the history of anticancer drugs, a general idea of the current drug discovery process for both small and large molecule drugs, and what tools might be coming next for the veterinary oncologist.
Learning Objectives:
- Gain a general knowledge of how a target-based drug discovery program works
- Gain a general knowledge of how a mAb-based drug is found
- Become familiar with some of the tools used to evaluate anticancer drugs during drug discovery
- Gain a general knowledge about the relationship between human drug discovery and how these drugs become available for veterinary use
RACE Application Status
This module has been submitted and approved for 0.5 hours of continuing education credit in jurisdictions which recognize AAVSB RACE approval.
For additional questions, please contact us at Learning@ACVIM.org.
Presenter
David Lowery, PhD
Chief Product Development Manager
PetMedix
Dr. Lowery is currently the Chief Product Development Officer for PetMedix, a U.K.-based biotech that makes antibody drugs for Animal Health applications. He received a B.S. in Biochemistry from University of Illinois, and a Ph.D. in Biochemistry from the University of Iowa in 1988. David has worked in industrial pharmaceutical R&D his entire career (30+ years), working for larger pharmaceutical companies like The Upjohn Company, Pharmacia, Pfizer, Novartis, Elanco, Merial, and Boehringer Ingelheim. He has worked on vaccine, pharmaceutical, parasiticide, and biopharmaceutical projects. Although the majority of that time has been within the R&D departments of the Animal Health companies, the work has always been closely associated with a human health pharmaceutical partner.